GSK: positive opinion from CHMP

(CercleFinance.com) - GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the use of an all-liquid, single-vial presentation of Menveo to help protect against invasive meningococcal disease (IMD).


If approved, the all-liquid presentation will offer healthcare providers an option that does not require reconstitution of Menveo (MenACWY vaccine) prior to use.

Philip Dormitzer, Head of Global Vaccine Research and Development at GSK, said that as the world leader in meningococcal vaccines, we are committed to finding innovative solutions that simplify immunization against bacterial meningitis, support vaccine uptake and help protect as many people as possible against this devastating disease. We will continue our efforts to help prevent this disease in at-risk populations in the European Union.

GSK's MenACWY vaccine has received regulatory approval in more than 60 countries, and more than 82 million doses have been distributed worldwide since 2010. More than 6 million doses have been distributed to European countries since 2017.


Copyright (c) 2024 CercleFinance.com. All rights reserved.